Business
Corxel will use the fundraising proceeds to advance the oral GLP-1 therapy CX11 through mid-stage development in the U.S., as well as prepare for its Phase III studies.
FEATURED STORIES
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Under the agreement, Merck can use Synthekine’s surrogate cytokine agonist platform to discover, develop, and sell new cytokine-based treatments for up to two cytokine targets.
Albert Bourla, chief executive officer of Pfizer, argued this week that politicians were approaching the problem of drug pricing the wrong way — as usual.
The 174,000 square-foot location will house a fully-equipped production plant to create its initial programs for Type 1 diabetes, a specific genetic cause of autism, galactosemia, and more.
Yet another busy week for clinical trial news. Here’s a look.
The life sciences industry continues to be one of the fastest growing industries in the world as the end of the year draws near.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Alnylam Chief Executive Officer Dr. John Maraganore, who has guided the company’s RNAi therapies from concept to commercialization, is handing over the reins of the company at the end of the year.
Collaboration is key to faster breakthroughs. The NIH, FDA, and 15 private organizations have announced they are joining forces for the sake of the 30 million Americans suffering from a rare disease.
Although the literature suggests this condition may affect 200 people globally, Williams and his team think the numbers are higher.
The osteoarthritis drug tanezumab gets permanent leave from the market. The decision of stopping production was due to negative feedback from the regulators.